Summary
Venetoclax, an oral targeted therapy, in combination with other targetd therapies (obinutuzumab or acalabrutinib) is being investigated in this study for the treatment of previously untreated chronic lymphocytic leukaemia (CLL). You may also be eligible for this study if you have previously untreated small lymphocytic lymphoma (SLL).
Study doctors will put eligible participants in one of four groups, called treatment arms. Participants will receive oral venetoclax in combination with intravenously (IV) infused obinutuzumab or oral acalabrutinib in different dosing schemes as part of treatment.
- Participants in Arm A will receive oral venetoclax + IV infused obinutuzumab, with a 5 week venetoclax ramp-up.
- Participants in Arm B will receive oral venetoclax + oral acalabrutinib, with a 5 week venetoclax ramp-up.
- Participants in Arm C and Arm D will receive oral venetoclax + oral acalabrutinib, with differing venetoclax ramp-up periods.
The total study duration is approximately 28 months.
There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.